SEO URLwww.firestrike.ai/deals/arcellx-gilead-sciences-acquisition-2026-36
acquisitionAnnounced · Apr 29, 2026BiotechnologySource · CredibleArticle · Factual
Gilead Sciences acquires Arcellx
David Najork · Founding Software Engineer
Announced · Updated · 1 min read
Deal value
$6.6B
Target
Arcellx
NASDAQ: ACLX · Redwood City, California
Acquirer
Gilead Sciences
Full Acquisition
Status
Pending
Gilead Sciences agreed to acquire Arcellx. Reported deal value: $6.6B. Status: Pending. Sector: Biotechnology. Target headquarters context: Redwood City, California, United States.
This page summarizes publicly available information about the transaction as of 2026-04-29. Figures and status may change as filings and press coverage update.
About Gilead Sciences Gilead Sciences , Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people
Deal timeline
Announced
Apr 29, 2026 · biospace.com
Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.
Sector context
This transaction is classified in Biotechnology with a reported deal value of $6.6B. Figures and status may change as sources update.
Sources: biospace.com · Primary article · FireStrike proprietary index